UroGen Pharma (URGN) Expected to Announce Quarterly Earnings on Monday

UroGen Pharma (NASDAQ:URGN) is anticipated to release its Q1 2025 earnings data before the market opens on Monday, May 12th. Analysts expect UroGen Pharma to post earnings of ($0.83) per share and revenue of $22.71 million for the quarter.

UroGen Pharma (NASDAQ:URGN) last announced its earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million for the quarter, compared to analyst estimates of $25.25 million. On average, analysts expect UroGen Pharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

UroGen Pharma Trading Down 3.0 %

Shares of UroGen Pharma stock opened at $10.35 on Friday. UroGen Pharma has a 1-year low of $8.94 and a 1-year high of $20.70. The company’s fifty day simple moving average is $10.64 and its 200-day simple moving average is $10.99. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The stock has a market capitalization of $477.21 million, a PE ratio of -3.29 and a beta of 0.66.

Wall Street Analysts Forecast Growth

A number of analysts have commented on URGN shares. The Goldman Sachs Group reduced their price target on UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating for the company in a research report on Thursday, April 17th. Guggenheim restated a “buy” rating on shares of UroGen Pharma in a research note on Tuesday, April 29th. D. Boral Capital reissued a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a research note on Thursday. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of UroGen Pharma in a research note on Monday, April 28th. Finally, LADENBURG THALM/SH SH began coverage on UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target for the company. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, UroGen Pharma has a consensus rating of “Buy” and a consensus price target of $32.86.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.